Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2015 Research Report

PUNE, India, September 1, 2015 /PRNewswire/ --

Diabetes, Metabolic Syndrome and Cardiovascular Disease is a new 2015 market research report that charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD).

Complete report on Diabetes, Metabolic Syndrome and Cardiovascular Disease market spread across 270 pages, profiling 66 companies and supported with 106 tables and 35 figures is now available at http://www.reportsnreports.com/reports/75197-diabetes-metabolic-syndrome-and-cardiovascular-disease.html .

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occurs along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed.

This research report on Diabetes, Metabolic Syndrome and Cardiovascular Disease market charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.

Companies profiled in this 2015 diabetes, metabolic syndrome and cardiovascular disease market research include A. Menarini, Abbott Laboratories, Abbvie, Amgen, Amylin Pharmaceuticals (bought by Bristol-Myers Squibb), Animas (part of Johnson & Johnson), Asante, Astellas Pharma, Inc., AstraZeneca PLC, Bayer, Becton, Dickinson and Company, Biocon, Biodel, BodyMedia, Boehringer Ingelheim, Bristol Myers Squibb, Cellnovo, CeQur, ConjuChem, Daiichi Sankyo, Dance Biopharm, Debiotech, DexCom, Echo Therapeutics, Inc., Eli Lilly, FIFTY50 Medical, Inc., Flamel Technologies, Generex Biotechnology Corporation, GlaxoSmithKline PLC, Halozyme Therapeutics, Insulet, Insuline Medical Ltd., Intarcia Therapeutics, Inc., Janssen Research & Development, Johnson & Johnson, Kowa Pharmaceuticals, Lexicon Pharmaceuticals, MannKind Corporation, Medipacs, Medtronic, Merck & Company, Inc., Mitsubishi Tanabe Pharma Corporation, Novartis, Novo Nordisk, Oramed Pharmaceuticals, Orexigen Therapeutics, Inc, Owen Mumford, PhaseBio Pharmaceuticals, Pfizer, Prometheon Pharma, Roche Diagnostics, Sanofi, Sernova, Smiths Medical, SOOIL Development, Taisho Pharmaceuticals, Takeda, Tandem Diabetes Care, Inc, Theracos, Inc., Transdermal Specialties, Inc., Valeritas, ViaCyte, Inc. (formerly Novocell), Vivus, Inc., vTv Therapeutics (formerly TransTech Pharma), Ypsomed Holding and Zealand Pharma. Order a copy of Diabetes, Metabolic Syndrome and Cardiovascular Disease market 2015 research report at http://www.reportsnreports.com/Purchase.aspx?name=75197 .

On a related note, another research titled Gene Therapy Cardiovascular Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape provides the information across the gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, funding and licensing opportunities. The Gene Therapy Cardiovascular Report provides the target gene name, localization of gene, molecular function of target with descriptive mechanism of action. It has covered 25+ gene therapies covering 20+ Pharmaceutical companies. Studies are performed for approximately 15+ specific indications under Cardiovascular. The Companies are utilizing 8 different technology platforms which have its own uniqueness and robustness. The Report is also giving insights about the vectors usage in Gene therapy which is approximately 46% for viral vectors, 4% for RNAi Therapeutics and 50% for Non Viral vectors. The Report is also giving early winners of the Cardiovascular gene therapy market using a proprietary Matrix Model. Supported with 20 tables, 18 figures and spread across 100 pages, this research report is available t http://www.reportsnreports.com/reports/328008-gene-therapy-cardiovascular-insight-pipeline-assessment-market-trend-technology-and-competitive-landscape.html .

Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ and on the biotechnology industry at http://www.reportsnreports.com/market-research/biotechnology/ .

About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:  

Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
[email protected]

Connect With Us on:  

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds:   http://www.reportsnreports.com/feed/l-latestreports.xml